422 related articles for article (PubMed ID: 25771365)
1. Radioimmunotherapy of Metastatic Prostate Cancer with ¹⁷⁷Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal Antibody.
Vallabhajosula S; Nikolopoulou A; Jhanwar YS; Kaur G; Tagawa ST; Nanus DM; Bander NH; Goldsmith SJ
Curr Radiopharm; 2016; 9(1):44-53. PubMed ID: 25771365
[TBL] [Abstract][Full Text] [Related]
2. Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (
Tagawa ST; Vallabhajosula S; Christos PJ; Jhanwar YS; Batra JS; Lam L; Osborne J; Beltran H; Molina AM; Goldsmith SJ; Bander NH; Nanus DM
Cancer; 2019 Aug; 125(15):2561-2569. PubMed ID: 31012963
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer.
Tagawa ST; Milowsky MI; Morris M; Vallabhajosula S; Christos P; Akhtar NH; Osborne J; Goldsmith SJ; Larson S; Taskar NP; Scher HI; Bander NH; Nanus DM
Clin Cancer Res; 2013 Sep; 19(18):5182-91. PubMed ID: 23714732
[TBL] [Abstract][Full Text] [Related]
4. [
Hofman MS; Violet J; Hicks RJ; Ferdinandus J; Thang SP; Akhurst T; Iravani A; Kong G; Ravi Kumar A; Murphy DG; Eu P; Jackson P; Scalzo M; Williams SG; Sandhu S
Lancet Oncol; 2018 Jun; 19(6):825-833. PubMed ID: 29752180
[TBL] [Abstract][Full Text] [Related]
5. Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): studies in nude mice.
Vallabhajosula S; Smith-Jones PM; Navarro V; Goldsmith SJ; Bander NH
Prostate; 2004 Feb; 58(2):145-55. PubMed ID: 14716739
[TBL] [Abstract][Full Text] [Related]
6. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor.
Smith-Jones PM; Vallabhajosula S; Navarro V; Bastidas D; Goldsmith SJ; Bander NH
J Nucl Med; 2003 Apr; 44(4):610-7. PubMed ID: 12679407
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (
Batra JS; Niaz MJ; Whang YE; Sheikh A; Thomas C; Christos P; Vallabhajosula S; Jhanwar YS; Molina AM; Nanus DM; Osborne JR; Bander NH; Tagawa ST
Urol Oncol; 2020 Nov; 38(11):848.e9-848.e16. PubMed ID: 32600929
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic Multidose Preparation of a Ready-to-Use
Chakraborty A; Mitra A; Tawate M; Sahoo S; Lad S; Rakshit S; Gaikwad S; Basu S; Shimpi H; Banerjee S
Cancer Biother Radiopharm; 2021 Oct; 36(8):682-692. PubMed ID: 34402687
[No Abstract] [Full Text] [Related]
9. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer.
Bander NH; Milowsky MI; Nanus DM; Kostakoglu L; Vallabhajosula S; Goldsmith SJ
J Clin Oncol; 2005 Jul; 23(21):4591-601. PubMed ID: 15837970
[TBL] [Abstract][Full Text] [Related]
10. PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617.
Kratochwil C; Giesel FL; Stefanova M; Benešová M; Bronzel M; Afshar-Oromieh A; Mier W; Eder M; Kopka K; Haberkorn U
J Nucl Med; 2016 Aug; 57(8):1170-6. PubMed ID: 26985056
[TBL] [Abstract][Full Text] [Related]
11. Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer.
Kabasakal L; AbuQbeitah M; Aygün A; Yeyin N; Ocak M; Demirci E; Toklu T
Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1976-83. PubMed ID: 26227531
[TBL] [Abstract][Full Text] [Related]
12. Imaging expression of prostate-specific membrane antigen and response to PSMA-targeted β-emitting radionuclide therapies in metastatic castration-resistant prostate cancer.
Vlachostergios PJ; Niaz MJ; Skafida M; Mosallaie SA; Thomas C; Christos PJ; Osborne JR; Molina AM; Nanus DM; Bander NH; Tagawa ST
Prostate; 2021 Apr; 81(5):279-285. PubMed ID: 33465252
[TBL] [Abstract][Full Text] [Related]
13. Lutetium-177 Labelled Anti-PSMA Monoclonal Antibody (Lu-TLX591) Therapy for Metastatic Prostate Cancer: Treatment Toxicity and Outcomes.
Nguyen H; Hird K; Cardaci J; Smith S; Lenzo NP
Mol Diagn Ther; 2024 May; 28(3):291-299. PubMed ID: 38446353
[TBL] [Abstract][Full Text] [Related]
14. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen.
Bander NH; Trabulsi EJ; Kostakoglu L; Yao D; Vallabhajosula S; Smith-Jones P; Joyce MA; Milowsky M; Nanus DM; Goldsmith SJ
J Urol; 2003 Nov; 170(5):1717-21. PubMed ID: 14532761
[TBL] [Abstract][Full Text] [Related]
15. Pilot Study of Hyperfractionated Dosing of Lutetium-177-Labeled Antiprostate-Specific Membrane Antigen Monoclonal Antibody J591 (
Niaz MJ; Batra JS; Walsh RD; Ramirez-Fort MK; Vallabhajosula S; Jhanwar YS; Molina AM; Nanus DM; Osborne JR; Bander NH; Tagawa ST
Oncologist; 2020 Jun; 25(6):477-e895. PubMed ID: 31999003
[TBL] [Abstract][Full Text] [Related]
16. Early Prostate-Specific Antigen Changes and Clinical Outcome After
Gafita A; Heck MM; Rauscher I; Tauber R; Cala L; Franz C; D'Alessandria C; Retz M; Weber WA; Eiber M
J Nucl Med; 2020 Oct; 61(10):1476-1483. PubMed ID: 32111687
[TBL] [Abstract][Full Text] [Related]
17. Prostate-Specific Membrane Antigen-Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of
Tagawa ST; Thomas C; Sartor AO; Sun M; Stangl-Kremser J; Bissassar M; Vallabhajosula S; Huicochea Castellanos S; Nauseef JT; Sternberg CN; Molina A; Ballman K; Nanus DM; Osborne JR; Bander NH
J Clin Oncol; 2024 Mar; 42(7):842-851. PubMed ID: 37922438
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer.
Ahmadzadehfar H; Eppard E; Kürpig S; Fimmers R; Yordanova A; Schlenkhoff CD; Gärtner F; Rogenhofer S; Essler M
Oncotarget; 2016 Mar; 7(11):12477-88. PubMed ID: 26871285
[TBL] [Abstract][Full Text] [Related]
19. Salivary toxicity from PSMA-targeted radiopharmaceuticals: What we have learned and where we are going.
Muniz M; Loprinzi CL; Orme JJ; Koch RM; Mahmoud AM; Kase AM; Riaz IB; Andrews JR; Thorpe MP; Johnson GB; Kendi AT; Kwon ED; Nauseef JT; Morgans AK; Sartor O; Childs DS
Cancer Treat Rev; 2024 Jun; 127():102748. PubMed ID: 38703593
[TBL] [Abstract][Full Text] [Related]
20. Enhancing Treatment Efficacy of
Kuo HT; Merkens H; Zhang Z; Uribe CF; Lau J; Zhang C; Colpo N; Lin KS; Bénard F
Mol Pharm; 2018 Nov; 15(11):5183-5191. PubMed ID: 30251544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
